These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32311956)

  • 1. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study.
    Zeng J; Qu P; Hu Y; Sun P; Qi J; Zhao G; Gao Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19714. PubMed ID: 32311956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-classification of uterine cervical cancer cases treated with radical hysterectomy based on the 2018 FIGO staging system.
    Osaku D; Komatsu H; Okawa M; Iida Y; Sato S; Oishi T; Harada T
    Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1054-1058. PubMed ID: 34794737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?
    Ayhan A; Aslan K; Bulut AN; Akilli H; Öz M; Haberal A; Meydanli MM
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():209-214. PubMed ID: 31325847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors.
    Yan DD; Tang Q; Chen JH; Tu YQ; Lv XJ
    Cancer Manag Res; 2019; 11():5473-5480. PubMed ID: 31354353
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.
    Wright JD; Matsuo K; Huang Y; Tergas AI; Hou JY; Khoury-Collado F; St Clair CM; Ananth CV; Neugut AI; Hershman DL
    Obstet Gynecol; 2019 Jul; 134(1):49-57. PubMed ID: 31188324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
    Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
    Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the FIGO 2018 staging system of cervical cancer: Retrospective analysis of FIGO 2009 stage IB1 cervical cancer with tumor under 2 cm.
    Takahashi M; Sakai K; Iwasa N; Wada M; Hino M; Kurahashi T; Ueno M; Nakagawa H
    J Obstet Gynaecol Res; 2021 May; 47(5):1871-1877. PubMed ID: 33611822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the 2018 FIGO cervical cancer staging system.
    Matsuo K; Machida H; Mandelbaum RS; Konishi I; Mikami M
    Gynecol Oncol; 2019 Jan; 152(1):87-93. PubMed ID: 30389105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage Migration in Cervical Cancer Using the FIGO 2018 Staging System: A Retrospective Survival Analysis Using a Single-Institution Patient Cohort.
    Vengaloor Thomas T; Reddy KK; Gandhi S; Nittala MR; Abraham A; Robinson W; Ridgway M; Packianathan S; Vijayakumar S
    Cureus; 2021 Nov; 13(11):e19289. PubMed ID: 34877225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying selection criteria for non-radical hysterectomy in FIGO stage IB cervical cancer.
    Kasamatsu T; Ishikawa M; Murakami N; Okada S; Ikeda SI; Kato T; Itami J
    J Obstet Gynaecol Res; 2019 Apr; 45(4):882-891. PubMed ID: 30672089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
    Lee JM; Lee KB; Nam JH; Ryu SY; Bae DS; Park JT; Kim SC; Cha SD; Kim KR; Song SY; Kang SB
    Ann Oncol; 2008 Feb; 19(2):321-6. PubMed ID: 17962205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.
    Atlan D; Touboul E; Deniaud-Alexandre E; Lefranc JP; Antoine JM; Jannet D; Lhuillier P; Uzan M; Huart J; Genestie C; Antoine M; Jamali M; Ganansia V; Milliez J; Uzan S; Blondon J
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):780-93. PubMed ID: 12377330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Operable stage IB and II cancer of the uterine neck: retrospective comparison between preoperative utero-vaginal curietherapy and initial surgery followed by radiotherapy].
    Atlan D; Touboul E; Deniaud-Alexandre E; Lefranc JP; Ganansia V; Bernard A; Antoine JM; Jannet D; Lhuillier PE; Uzan M; Genestie C; Antoine M; Jamali M; Milliez J; Uzan S; Blondon J
    Cancer Radiother; 2002 Jun; 6(4):217-37. PubMed ID: 12224488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
    Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
    Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
    Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
    van Kol KGG; Ebisch RMF; van der Aa M; Wenzel HB; Piek JMJ; Bekkers RLM
    Gynecol Oncol; 2023 Apr; 171():9-14. PubMed ID: 36804623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Para-aortic lymph node involvement revisited in the light of the revised 2018 FIGO staging system for cervical cancer.
    Ayhan A; Aslan K; Öz M; Tohma YA; Kuşçu E; Meydanli MM
    Arch Gynecol Obstet; 2019 Sep; 300(3):675-682. PubMed ID: 31263988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic results and surgical morbidity of laparoscopic nerve-sparing radical hysterectomy in the treatment of FIGO stage IB cervical cancer: long-term follow-up.
    Park NY; Chong GO; Hong DG; Cho YL; Park IS; Lee YS
    Int J Gynecol Cancer; 2011 Feb; 21(2):355-62. PubMed ID: 21270616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of laparoscopic and open radical hysterectomy in cervical cancer patients with tumor size ≤2 cm.
    Chen X; Zhao N; Ye P; Chen J; Nan X; Zhao H; Zhou K; Zhang Y; Xue J; Zhou H; Shang H; Zhu H; Leanne VM; Yan X
    Int J Gynecol Cancer; 2020 May; 30(5):564-571. PubMed ID: 32276941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival?
    Finan MA; DeCesare S; Fiorica JV; Chambers R; Hoffman MS; Kline RC; Roberts WS; Cavanagh D
    Gynecol Oncol; 1996 Aug; 62(2):139-47. PubMed ID: 8751541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.